Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland
Crossref DOI link: https://doi.org/10.1007/s12325-017-0614-8
Published Online: 2017-10-03
Published Print: 2017-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Soini, Erkki
Asseburg, Christian
Taiha, Maarit
Puolakka, Kari
Purcaru, Oana
Luosujärvi, Riitta
Funding for this research was provided by:
UCB Pharma
Text and Data Mining valid from 2017-10-01
Article History
Received: 22 May 2017
First Online: 3 October 2017